Cross-Sector entity
Of the tracked stories, 2 of 2 also mention GoodRx, the most common co-covered peer. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. Kymera Therapeutics appears in 2 tracked Cross-Sector stories from February 26, 2026.
2 verified stories tracked
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention GoodRx, the most common co-covered peer. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. Kymera Therapeutics appears in 2 tracked Cross-Sector stories from February 26, 2026. The tracked stories average 12 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kymera Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
